Clinical trial
Study of Eculizumab for Prevention and Treatment Reperfusion Injury in Kidney Transplantation.
NCT01756508 is registered in ClinicalTrials.gov with Russian Academy of Medical Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study of Eculizumab for Prevention and Treatment Reperfusion Injury in Kidney Transplantation.
- Lead sponsor
- Russian Academy of Medical Sciences
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 1, 2012
- Completion date
- December 1, 2017
- Enrollment
- 57 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
end-stage renal disease, graft reperfusion injury, kidney failure